v3.26.1
License Agreements (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Oct. 31, 2025
USD ($)
Milestone
shares
Nov. 30, 2020
shares
Sep. 30, 2020
item
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Jan. 31, 2025
USD ($)
May 31, 2021
USD ($)
Oct. 31, 2020
USD ($)
Nature of Business                  
Upfront payment paid       $ 35,000          
Acquired IPR&D expense       171,672          
2020 Xencor Agreement                  
Nature of Business                  
Number of antibody product candidates | item     3            
2020 Xencor Agreement | Series A preferred stock                  
Nature of Business                  
Number of preferred stock issued | shares   5,041,542              
2021 Xencor Agreement                  
Nature of Business                  
Regulatory milestone payments               $ 75,000  
Sales milestone payments               $ 385,000  
Development milestone expense           $ 10,000      
Viridian Agreement                  
Nature of Business                  
Reimbursable costs       200 $ 1,700        
Development milestone expense payable       0 $ 0        
Passthrough obligation             $ 21,000   $ 21,000
InnoCare Pharma Inc                  
Nature of Business                  
Contract manufacturing organization costs recognized       3,100          
Reimbursable costs       $ 2,200          
Non-refundable cash payment $ 35,000                
Number of shares agreed to be issued | shares 5,000,000                
Amount of contingent payment payable upon on occurrence of specified events $ 25,000                
Number of shares agreed to be issued upon on occurrence of specified events | shares 2,000,000                
Term milestone payments $ 20,000                
Regulatory milestones payable 20,000                
Future regulatory and commercial milestones payable $ 723,000                
Development, regulatory and commercial milestones payable $ 656,000                
Number of antibody product candidates | Milestone 2                
Acquired IPR&D expense $ 171,700